Close
  Indian J Med Microbiol
 

Figure 1: The somatodendritic regions containing the serotonergic 5-HT1A and 5-HT7 autoreceptors are located predominantly at the midbrain raphe nucleus which is highly rich in serotonergic neurons. The terminal presynaptic regions of their projected axons synapse with different cortical (prefrontal cortex) and subcortical (hippocampus, mesolimbic cortex, basal ganglia, and hypothalamus) areas of the brain to mediate different serotonergic neurotransmission signals in different neuropsychiatric disorders. The synergistic influence/combination of the full antagonism of the somatodendritic serotonergic 5-HT7 autoreceptor by an atypical antipsychotic and the partial agonism of the somatodendritic serotonergic 5-HT1A autoreceptor by an atypical antipsychotic in the presence of selective serotonin reuptake inhibitor or serotonin–norepinephrine reuptake inhibitor or noradrenergic α2-receptor antagonist with specific serotonergic receptors-2 and -3 antagonism or tricyclic antidepressant will enhance and produce fast disinhibition of the serotonergic neurotransmission signals from the midbrain raphe nucleus toward the prefrontal cortex, hippocampus and mesolimbic cortex, basal ganglia, and hypothalamus to mediate its respective therapeutic actions in depressive disorders, panic disorder, obsessive–compulsive disorder, and binge-eating disorder (bulimia nervosa); as the somatodendritic serotonergic 5-HT7 and 5-HT1A autoreceptors desensitization phenomenon has been bypassed by the full antagonistic and the partial agonistic (weak-mixed agonistic-antagonistic) effects of these two autoreceptors, respectively. That is, an atypical antipsychotic disinhibits different serotonergic neurotransmission signals from the midbrain raphe nucleus in different neuropsychiatric disorders to turn on serotonin neurotransmitter release from the terminal presynaptic regions in different cortical and subcortical areas

Figure 1: The somatodendritic regions containing the serotonergic 5-HT<sub>1A</Sub> and 5-HT<sub>7</Sub> autoreceptors are located predominantly at the midbrain raphe nucleus which is highly rich in serotonergic neurons. The terminal presynaptic regions of their projected axons synapse with different cortical (prefrontal cortex) and subcortical (hippocampus, mesolimbic cortex, basal ganglia, and hypothalamus) areas of the brain to mediate different serotonergic neurotransmission signals in different neuropsychiatric disorders. The synergistic influence/combination of the full antagonism of the somatodendritic serotonergic 5-HT<Sub>7</Sub> autoreceptor by an atypical antipsychotic and the partial agonism of the somatodendritic serotonergic 5-HT<Sub>1A</Sub> autoreceptor by an atypical antipsychotic in the presence of selective serotonin reuptake inhibitor or serotonin–norepinephrine reuptake inhibitor or noradrenergic α<sub>2</Sub>-receptor antagonist with specific serotonergic receptors-2 and  -3 antagonism or tricyclic antidepressant will enhance and produce fast disinhibition of the serotonergic neurotransmission signals from the midbrain raphe nucleus toward the prefrontal cortex, hippocampus and mesolimbic cortex, basal ganglia, and hypothalamus to mediate its respective therapeutic actions in depressive disorders, panic disorder, obsessive–compulsive disorder, and binge-eating disorder (bulimia nervosa); as the somatodendritic serotonergic 5-HT<sub>7</Sub> and 5-HT<sub>1A</Sub> autoreceptors desensitization phenomenon has been bypassed by the full antagonistic and the partial agonistic (weak-mixed agonistic-antagonistic) effects of these two autoreceptors, respectively. That is, an atypical antipsychotic disinhibits different serotonergic neurotransmission signals from the midbrain raphe nucleus in different neuropsychiatric disorders to turn on serotonin neurotransmitter release from the terminal presynaptic regions in different cortical and subcortical areas